AR signaling context and the apparent lack of synergy between AR-targeted therapy and PARP inhibition. [PDF]
Zhou S, Tsao CK.
europepmc +1 more source
IGF1R Induces ROS Formation in Mitochondria via MICU1 Leads to the Enzalutamide Resistance in Prostate Cancer. [PDF]
Li H +8 more
europepmc +1 more source
A Bioequivalence Study of Two Formulations of Enzalutamide Soft Capsules in Healthy Chinese Male Subjects. [PDF]
Wang J +10 more
europepmc +1 more source
Beyond pairwise comparisons of androgen receptor signaling inhibitors in nonmetastatic castration-resistant prostate cancer. [PDF]
Hara S.
europepmc +1 more source
AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial. [PDF]
Medina S +18 more
europepmc +1 more source
Reply to Zhou and Tsao: Synergy rarely underlies the benefits of combination cancer therapy. [PDF]
Traphagen Ho NA, Brown M.
europepmc +1 more source
Extensive Dural Metastasis as Initial Presentation of Metastatic Prostate Cancer: A Case Report With Durable Disease Control Following Multimodal Treatment. [PDF]
Wasilewski D +3 more
europepmc +1 more source
Insights from EMBARK: guiding clinical care and trial design. [PDF]
Wilson RJ, Schoen MW.
europepmc +1 more source
SPEN Inactivation Drives Resistance to Androgen Receptor Pathway Inhibitors in Metastatic Prostate Cancer. [PDF]
Blinka S +11 more
europepmc +1 more source
Refractory thrombocytopenia induced by enzalutamide combined with docetaxel chemotherapy in a metastatic castration-resistant prostate cancer patient with bone marrow metastasis: a case report and literature review. [PDF]
Chen Y, Liu J.
europepmc +1 more source

